electroCore Reports 28% Revenue Growth but Faces Net Loss in Q2 2026

electroCore, Inc. reported its financial results for the second quarter of 2026, revealing a net sales increase of 28% to $9.45 million compared to $7.38 million in the same period last year. For the first half of 2026, the company achieved net sales of $19.03 million, a 35% rise from $14.10 million in the first half of 2025. The growth in revenue was primarily driven by increased sales of its prescription products, particularly the gammaCore and Quell Fibromyalgia devices, which are sold predominantly to the U.S. Department of Veterans Affairs (VA). The VA accounted for approximately 75.8% of the company's revenue in the second quarter of 2026.

Despite the revenue growth, electroCore reported a net loss of $3.06 million for the second quarter, an improvement from a loss of $3.67 million in the same quarter of 2025. For the six months ended June 30, 2026, the net loss was $8.33 million, compared to $7.53 million in the prior year. The company’s operating expenses increased to $10.95 million in the second quarter, up from $9.95 million a year earlier, largely due to higher selling, general, and administrative costs, which rose by $0.7 million. Research and development expenses also increased, reflecting ongoing investments in product enhancements and clinical studies.

In terms of operational metrics, electroCore's cash, cash equivalents, and marketable securities totaled $10.0 million as of June 30, 2026, down from $11.6 million at the end of 2025. The company used $6.53 million in cash for operating activities during the first half of 2026, compared to $4.98 million in the same period of 2025. The increase in cash used was attributed to higher inventory levels and the timing of operating expenses. The company has historically funded its operations through equity and debt financing, and it continues to explore these avenues to support its growth strategy.

Strategically, electroCore has made significant moves, including the acquisition of NeuroMetrix, Inc. in May 2025, which has expanded its product offerings. The company has also entered into an At-The-Market Offering Agreement, allowing it to sell shares of common stock to raise additional capital. As of June 30, 2026, the company had approximately $15.7 million remaining for potential issuance under its 2025 Shelf Registration Statement. However, the company faces challenges, including a leadership transition following the retirement of its former CEO, which may impact operational efficiency and strategic execution.

Looking ahead, electroCore anticipates continued net losses as it works to increase market acceptance of its products. The company plans to invest in sales, marketing, and research and development to drive commercial activities. However, there are substantial doubts regarding its ability to maintain operations at planned levels without additional funding, raising concerns about its long-term viability. The company has indicated that it may need to significantly reduce its activities if it cannot secure sufficient cash flow and liquidity to fund its operations over the next 12 months.